Echocardiography

Cardiac ultrasound uses reflected sound waves (echos) to create images of anatomy inside the body. Echocardiograms are the primary cardiac imaging modality used to assess the heart and diagnose or track cardiac issues. Echo is the gold standard imaging modality to assess the heart, particularly with calculating left ventricular ejection fraction (LVEF), which is a measure of cardiac output. In addition to noninvasive standard transthoracic echo (TTE), invasive transesophgeal echo (TEE) is also used when clearer, more detailed imaging of the heart is needed. Both 3D and 4D echo echo systems are rapidly gaining wider adoption and enable new types of assessments, especially in the structural heart space and in transcatheter procedural guidance. Find news on general ultrasound imaging.

Standard transthoracic imaging planes for comprehensive right heart assessment. Several key views should be included in the standard echocardiographic assessment of the right heart. Image and caption courtesy of the American Society of Echocardiography.

ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Figure from the new ASE guideline for ultrasound guided vascular access, showing vessel and probe orientation on the transverse plane short axis (SAX) view perpendicular to the vessels, or in longitudinal long axis plane (LAX) coaxial to the vessels. Image courtesy of ASE

ASE shares new guidelines for ultrasound-guided vascular access

The American Society of Echocardiography included descriptions, diagrams and ultrasound images in the new document to make it as helpful as possible. 

Thumbnail

New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

The rapid rise of artificial intelligence (AI) has helped cardiologists, radiologists, nurses and other healthcare providers embrace precision medicine in a way that ensures more heart patients are receiving personalized care.

FDA clears AI screening tool for cardiac amyloidosis

Ultromics designed EchoGo Amyloidosis to evaluate routine echocardiogram results for signs of cardiac amyloidosis. It received the FDA's breakthrough device designation back in 2023.

The iCardio.ai EchoMeasure AI software to automate measurements for cardiac echo imaging. It was FDA cleared in October 2024.

FDA approves AI startup’s new software for echo assessments

iCardio.ai, co-founded by a cardiologist, is part of the Cedars-Sinai Accelerator program. The startup has already announced new partnerships with Viz.ai, Abbott and others in the cardiac health space. 

Ultrafast/high frame rate myocardial contrast echocardiography

Ultrafast myocardial contrast echocardiography shows early potential to evaluate CAD

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

ASE establishes vocabulary for cardiac POCUS to promote consistency

As cardiac point-of-care ultrasound use continues to grow outside of traditional echo labs, the American Society of Echocardiography is working to ensure everyone is on the same page.

Cardiac PET on the rise among U.S. cardiologists

SPECT is still the most common modality used to evaluate CAD patients, but cardiac PET is gaining more and more momentum.

Around the web

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.